The global recombinant vector vaccines market is expected to grow at a significant CAGR during the forecast period (2021-2027). The global recombinant vector vaccine market is being driven by rapid advances in molecular biology and genetic engineering. During the forecast period, the market is expected to rise rapidly. However, the market is anticipated to be constrained by a large number of pharmaceutical issues involved with the production of recombinant vector vaccines and severe regulatory requirements imposed by regulatory agencies.

Viruses attach themselves to a cell and inject their genetic material into it. Scientists have used this viral nature to create recombinant viral vector vaccines that use an attenuated virus as a carrier of genetic material into the host cell. Compared to other vaccines, recombinant vector vaccines have several advantages. T- cells are triggered by the recombinant vector vaccine approach, and antigens are then exposed to T-cell lymphocytes, resulting in a powerful cell-mediated immune response in the body against that particular antigen or pathogen. It also minimizes the requirement for repeat dosing to treat a certain condition. Recombinant vector vaccines can also be created using attenuated bacteria as a vector. In this example, genetic material is transferred into a bacterial vector, leading the bacteria to express antigens from other microorganisms on their surface, resulting in an immunological response. 

The development of recombinant vector vaccines for rabies, HIV, and measles is undergoing extensive research. Adenovirus vectors, poxvirus vectors, and alphavirus vectors are all being explored and used to make vaccines at the moment. Against specific bacteria, scientists must conduct extensive research and study. This vaccine is based on basic information such as how it infects a human or animal cell and what the infected cell's immune response is. Live attenuated vaccines, subunit vaccines, inactivated vaccines, conjugate vaccines, toxoid vaccines, DNA vaccines, and recombinant vector vaccines have all been developed by researchers. Recombinant DNA technology has been employed to develop novel vaccines in recent years. Scientists have used this method to generate recombinant vector vaccines against a variety of bacterial and viral illnesses. Recombinant vector vaccines are similar to DNA vaccines, however, they use an attenuated viral particle or bacterium as a vector instead of DNA.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Sanofi S.A., GlaxoSmithKline plc, and Novartis International AG, among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Recombinant Vector Vaccines Market Report Segmentation

By Type 

• Varicella

• Diphtheria

• Influenza

• BCG

• Rabies

• Polio

• Pertussis

• Hepatitis A

• Pneumococcal

• Hepatitis B

• Tetanus

• Others

By Application

• Adult

• Child

Global Recombinant Vector Vaccines Market by Region